US Stock MarketDetailed Quotes

IMRX Immuneering

Watchlist
  • 2.080
  • +0.030+1.46%
Trading Nov 27 09:57 ET
64.58MMarket Cap-1055P/E (TTM)

Immuneering Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Immuneering Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Immuneering Earnings Reports

  • Immuneering | 10-Q: Q3 2024 Earnings Report

    Nov 13 16:14 ET

  • Immuneering | 8-K: Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic

    Nov 13 16:08 ET

  • Immuneering | 8-K: Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 -

    Aug 6 16:16 ET

  • Immuneering | 10-Q: Q2 2024 Earnings Report

    Aug 6 16:14 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 27, 2024

    Buy

    • Buy

      66.67%

    • Hold

      33.33%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data